Expertise in
7
conditions

Dr. Kirsten Boughan

Hematology
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 
Expertise in
7
conditions
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 

Overview

Kirsten Boughan is a Hematologist practicing medicine in Cleveland, Ohio.

Dr. Boughan is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Burkitt Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 10 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in PA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

University Hospitals
11100 Euclid Ave, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Study Phase: Phase 2
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
Pilot Study to Develop a Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing Blood and Marrow Transplantation
Pilot Study to Develop a Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing Blood and Marrow Transplantation
Enrollment Status: Completed
Publish Date: August 05, 2025
Intervention Type: Other
Study Phase: Not Applicable
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 01, 2025
Intervention Type: Drug, Radiation, Procedure, Biological
Study Drugs: Fludarabine, Cyclophosphamide, Thiotepa
Study Phase: Phase 2
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
Enrollment Status: Completed
Publish Date: April 29, 2024
Intervention Type: Procedure, Drug
Study Drug: Fludarabine
Study Phase: Phase 1
View 9 Less Clinical Trials

21 Total Publications

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial.
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial.
Journal: EClinicalMedicine
Published: May 06, 2024
Similar Doctors
Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

Cleveland Clinic

8950 Euclid Ave, 
Cleveland, OH 
 (0.9 miles away)
216-444-8950
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jaroslaw Maciejewski is a Hematologist practicing medicine in Cleveland, Ohio. Dr. Maciejewski is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Aplastic Anemia, Paroxysmal Cold Hemoglobinuria, Bone Marrow Transplant, and Splenectomy.

Expertise in
28
conditions
Dr. Anjali Advani
Hematology | Oncology
Expertise in
28
conditions
Dr. Anjali Advani
Hematology | Oncology
Referral may be required

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.6 miles away)
866-223-8100
Experience:
34+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anjali Advani is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. She has been practicing medicine for over 34 years. Dr. Advani is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Advani is board certified in American Board Of Internal Medicine, 2003.

Expertise in
38
conditions
Expertise in
38
conditions
Referral may be required

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (0.8 miles away)
216-444-2200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matt Kalaycio is a Hematologist practicing medicine in Cleveland, Ohio. Dr. Kalaycio is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Kirsten Boughan

How do I make an appointment with Dr. Kirsten Boughan?

You can book an appointment with Dr. Kirsten Boughan by calling their office at 216-844-3951. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kirsten Boughan a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kirsten Boughan is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kirsten Boughan specialize in?

While Dr. Kirsten Boughan is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Burkitt Lymphoma, and B-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Kirsten Boughan participate in research or clinical trials?

Yes. Dr. Kirsten Boughan has published 21 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Kirsten Boughan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Boughan's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile